1. Classification of pancreatic lesions | ПРЕЦИЗИОННАЯ ОНКОЛОГИЯ

1. Classification of pancreatic lesions

%d0%b1%d0%bb%d0%be%d0%ba%d0%bd%d0%be%d1%82

CREATE YOUR OWN POST

You need to register on site.  Post will be published after being moderated

Introduction

The new revised WHO classification of tumors of the pancreas includes both exocrine and endocrine neoplasms in one classification (Table 1.1) [1]. This chapter will briefly review the major exocrine tumors, which are covered in more detail in subsequent chapters. A more detailed discussion of the classification of precursor pancreatic ductal lesions and pancreatic neuroendocrine tumors of the pancreas will also be provided in this chapter.

Classification of solid exocrine tumors of the pancreas

Ductal adenocarcinoma

Ductal adenocarcinoma and its variants make up more than 90% of all malignant exocrine pancreatic tumors. About two thirds of ductal adenocarcinomas occur in the head of the gland; the rest occur in the body or tail, or diffusely throughout the pancreas. They are characterized by an intense desmoplastic reaction in which duct-like structures of varying degrees of differentiation are seen. It comprises extracellular matrix together with a number of different host cell types, including fibroblasts, small endothelial-lined vessels, residual normal epithelia, and a variety of inflammatory cells which are both locally derived and recruited from the circulation [2]. The interplay between all these cells types and the pancreatic cancer cells influences new blood vessel formation, invasion, metastases, and evasion of the host immune system [3]. Because of their proximity to the intrapancreatic portion of the common bile duct, tumors in the head usually produce jaundice since they compress and obstruct the bile duct as they grow. They often obstruct the pancreatic duct as well, and although steatorrhea may result, there may not be any obvious symptoms. Tumors of the head of the pancreas are usually at least 2 cm in diameter when they are first diagnosed. Most tumors that are resected have a median diameter of 2.5–3.5 cm. Tumors of the body and tail commonly are larger (5–7 cm) and more advanced when they are discovered because they do not produce symptoms as early as head tumors do. The symptoms from tumors in the body and tail are usually caused by malignant infiltration of the retroperitoneal structures and nerves, which produces pain. By the time the diagnosis is made, almost all are unresectable. Nevertheless, there is evidence that resectable body tumors have a similar prognosis to resectable tumors in the head of the gland. Approximately 70–80% of adenocarcinomas of the head of the pancreas have metastasized to regional lymph nodes by the time they are discovered, which worsens the prognosis but does not preclude cure. These tumors also commonly invade lymphatic channels and perineural spaces. The prognosis is also influenced by the degree of tumor differentiation and by the presence of invasion of the retroperitoneal tissues adjacent to the cancer. The best outcome is seen in patients who have well-differentiated neoplasms, without retroperitoneal invasion or lymph node metastases. Distant metastases (e.g., lung) may occur, but pancreatic cancer typically infiltrates locally into the adjacent structures (e.g., stomach, duodenum, colon, transverse mesocolon, portal and superior mesenteric veins, superior mesenteric artery). The liver is the most common site of intraabdominal metastasis, and peritoneal seeding of the tumor is also seen. In patients without distant spread, vascular invasion by tumor is the most common reason for unresectability.

Table 1.1. WHO histologic classification of tumors of the exocrine and endocrine pancreas

  • Exocrine
    • Epithelial tumors
      • Benign
        • Serous cystadenoma
        • Mucinous cystadenoma
        • Intraductal papillary-mucinous adenoma
        • Mature teratoma
      • Borderline (uncertain malignant potential)
        • Mucinous cystic neoplasm with moderate dysplasia
        • Intraductal papillary-mucinous neoplasm with moderate dysplasia
        • Solid-pseudopapillary neoplasm
      • Malignant
        • Ductal adenocarcinoma
          • Mucinous noncystic carcinoma
          • Signet ring cell carcinoma
          • Adenosquamous carcinoma
          • Undifferentiated (anaplastic) carcinoma
          • Undifferentiated carcinoma with osteoclast-like giant cells
          • Mixed ductal–endocrine carcinoma
        • Serous cystadenocarcinoma
        • Mucinous cystadenocarcinoma
          • Noninvasive
          • Invasive
        • Intraductal papillary mucinous carcinoma
          • Noninvasive
          • Invasive
        • Acinar cell carcinoma
        • Acinar cell cystadenocarcinoma
        • Mixed acinar–endocrine carcinoma
        • Pancreatoblastoma
        • Solid-pseudopapillary carcinoma
        • Others
      • Nonepithelial tumors
        • Mesenchymal tumors
          • Lymphangioma
          • Lipoma
          • Solitary fibrous tumor
          • Ewing sarcoma
          • Desmoplastic small round cell tumor
          • Perivascular epithelioid cell neoplasm
        • Lymphomas
          • Diffuse large B-cell lymphoma (DLBCL)
        • Secondary tumors
      • Endocrine
        • Pancreatic neuroendocrine microadenoma
        • Neuroendocrine tumor G1 (NET G1)/Carcinoid
        • Neuroendocrine tumor G2 (NET G2)
        • Neuroendocrine carcinoma
          • Large cell neuroendocrine carcinoma
          • Small cell neuroendocrine carcinoma
        • Functional PNET
          • Gastrinoma, malignant
          • Glucagonoma, malignant
          • Insulin-producing carcinoma (insulinoma)
          • Somatostatinoma, malignant
          • Vipoma, malignant

The most widely accepted staging system for pancreatic cancer is the American Joint Committee on Cancer (in cooperation with the TNM committee of the International Union Against Cancer), which is shown in Table 1.2 [4]. Although this system is prognostic for overall survival, it is not particularly useful in guiding treatment, because some patients with advancedstage disease (i.e., stage IVA) may be candidates for surgical resection, whereas others may not. For this reason, pancreatic cancer patients are generally classified by physicians as having resectable, locally advanced, or metastatic disease. Other histologic variants of pancreatic ductal adenocarcinoma have been described, including mucinous noncystic carcinoma, signet ring cell carcinoma, adenosquamous carcinoma, undifferentiated (anaplastic) carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, and mixed ductal–endocrine carcinoma.


Текст защищен. Пожалуйста, введите логин и паспорт или зарегистрируйтесь. Enter your username and password to gain access to this review.
:
:

References

  1. Chapter 12—Tumours of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
  2. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101(4):887–907.
  3. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839–49.
  4. Edge S, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer staging manual. 7th ed. New York: Springer; 2010.
  5. Colombo P, Arizzi C, Roncalli M. Acinar cell cystadenocarcinoma of the pancreas: report of rare case and review of the literature. Hum Pathol. 2004;35(12): 1568–71.
  6. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20(24):4673–8.
  7. Balasundaram C, Luthra M, Chavalitdhamrong D, Chow J, Khan H, Endres PJ. Pancreatoblastoma: a rare tumor still evolving in clinical presentation and histology. JOP. 2012;13(3):301–3.
  8. Naito Y, Okabe Y, Kawahara A, Taira T, Yamagushi T, Abe H, et al. Guide to diagnosing primary pancreatic lymphoma, B-cell type: immunocytochemistry improves the diagnostic accuracy of endoscopic ultrasonography-guided fine needle aspiration cytology. Diagn Cytopathol. 2012;40(8):732–6.
  9. Farrell JJ, Fernandez-del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology. 2013;144(6):1303–15.
  10. de Jong K, Nio C, Mearadji B, Phoa S, Engelbrecht M, Dijkgraaf M, et al. Disappointing interobserver agreement among radiologists for a classifying diagnosis of pancreatic cysts using magnetic resonance imaging. Pancreas. 2012;41(2):278–82.
  11. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S. Prevalence of unsuspected pancreatic cysts on MDCT. Am J Roentgenol. 2008;191:802–7.
  12. Galanis C, Zamani A, Cameron JL, Campbell KA, Lillemoe KD, Caparelli D, et al. Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg. 2007;11:820–6.
  13. Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW, Fernandez-del Castillo C. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg. 2005; 242(3):413–9; discussion 419–21.
  14. Le Borgne J, de Calan L, Partensky C, FSA. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional restrospective study of 398 cases. Ann Surg. 1999;230:152–61.
  15. Bassi C, Salvia R, Molinari E, Biasutti C, Falconi M, Pederzoli P. Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa? World J Surg. 2003;27:319–23.
  16. Fernбndez-del Castillo C, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2010;139:708–13.
  17. Valsangkar NP, MoralesOyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152:S4–12.
  18. Crippa S, Salvia R, Warshaw AL, Dominguez I, Bassi C, Falconi M, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008;247:571–9.
  19. Yamao K, Yanagisawa A, Takahashi K, Kimura W, Doi R, Fukushima N, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan Pancreas Society. Pancreas. 2011;40:67–71.
  20. Le Baleur Y, Couvelard A, Vullierme MP, Sauvanet A, Hammel P, Rebours V, et al. Mucinous cystic neoplasms of the pancreas: definition of preoperative imaging criteria for high-risk lesions. Pancreatology. 2011;11:495–9.
  21. Vassos N, Agaimy A, Klein P, Hohenberger W, Croner RS. Solid-pseudopapillary neoplasm (SPN) of the pancreas: case series and literature review on an enigmatic entity. Int J Clin Exp Pathol. 2013;6(6): 1051–9.
  22. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg. 2005;200(6):965–72.
  23. Reddy S, Cameron JL, Scudiere J, Hruban RH, Fishman EK, Ahuja N, et al. Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a single-institutional series. J Am Coll Surg. 2009;208:950–9.
  24. Butte JM, Brennan MF, Gonen M, Tang LH, D’Angelica M, Fong Y, et al. Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastrointest Surg. 2011;15:350–7.
  25. Sommers SM, Murphy SA, Warren S. Pancreatic duct hyperplasia and cancer. Arch Pathol. 1954;27: 629–40.
  26. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977–87.
  27. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1766–73.
0